Pleomorphic liposarcoma
Abstract
Pleomorphic liposarcoma is the rarest and the most aggressive type of liposarcoma which most commonly arises in proximal extremities. It is rare in general population, with a higher incidence in older age. We present a case of a 65-year-old patient with a tumor-related change localized in the medial proximal area of the left femur. After extirpation, the tumor was treated with radiotherapy and subsequently due to recurrence chemotherapy was initiated. Therapeutic options are adapted to each patient individually and most frequently involve surgical extirpation and radiotherapy, while in certain cases chemotherapy is needed as well.
Downloads
References
Ryan CW, Meyer J. Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma. In: UpToDate. http://www.uptodate.com/contents/clinical-presentation-histopathology-diagnostic-evaluation-and-staging-of-soft-tissue-sarcoma (accessed 14 March 2016).
Gupta M, Nigam S, Ranjan R. Pleomorphic liposarcoma of the scapula in a young adult female. A Rare Entity. J Pioneer Med Sci 2015;5(4): 127–129.
Ortiz-Ibánez B, Amaya JV, Baixauli F, Angulo M, Mayordomo-Aranda E, Barrios C. Surgical resection of massive liposarcomas at the extremities: a 10-year experience in a referral musculoskeletal sarcoma unit. World J Surg Oncol 2015;13: 206. Published online 2015 Jun 25. doi: 10.1186/s12957-015-0622-6 (accessed 14 March 2016).
DeLaney TF, Harmon DC, Gebhardt MC. Local treatment for primary soft tissue sarcoma of the extremities and chest wall. In: UpToDate. http://www.uptodate.com/contents/local-treatment-for-primarysoft-tissue-sarcoma-of-the-extremities-and-chest-wall (accessed 14 March 2016).
Raut CP, George S, Demetri GD. Surgical treatment and other localized therapy for metastatic soft tissue sarcoma. In: UpToDate. http://www.uptodate.com/contents/surgical-treatment-and-otherlocalized-therapy-for-metastatic-soft-tissue-sarcoma (accessed 14 March 2016).
Maki R. Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities. In: UpToDate. http://www.uptodate.com/contents/adjuvant-and-neoadjuvant-chemotherapy-for-softtissue-sarcoma-of-the-extremities (accessed 14 March 2016).
Woll PJ, Reichardt P, Le Cesne A, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. For the EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group Sarcoma Disease Site Committee. Lancet Oncol. 2012;13(10): 1045.
Petrioli R, Coratti A, Correale P, et al. Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma. Clin Oncol. 2002 Oct;25(5): 468–473.
Brodowicz T, Schwameis E, Widder J, et al. Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma. A Prospective Randomized Feasibility Trial. Sarcoma. 2000;4(4): 15160. doi:10.1080/13577140020025869 (accessed 14 March 2016).
Suzanne George, MD. Systemic treatment of metastatic soft tissue sarcoma. In: UpToDate. http://www.uptodate.com/contents/systemic-treatment-of-metastatic-soft-tissue-sarcoma (accessed 14 March 2016).
Copyright (c) 2016 Acta Chirurgica Croatica
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby authorize the Acta Chirurgica Croatica (ACC) to publish their work.
The authors are aware that although ACC is Open Access journal, the copyright of all material published is vested in ACC. Open access articles are freely available to read, download, and share from the time of publication under the terms of the Creative Commons License Attribution ‐ NonCommerical No Derivative (CC BY‐NC‐ND) license. This license does not permit reuse for any commercial purposes nor does it cover the reuse or modification of individual elements of the work (such as figures, tables, etc.) in the creation of derivative works without specific permission of ACC and appropriate acknowledgment of its source. The authors permit ACC to allow third parties to copy any part of the work without asking for permission, provided that the reference to the source is given and that this is not done for commercial purposes. Except for copyright, other proprietary rights related to the work (e.g., patent or other rights to any process or procedure) shall be retained by the author. To reproduce any text, figures, tables, or illustrations from this work in future works of their own, the author must obtain written permission from ACC.
Each of the author(s) hereby also grants permission to ACC to use such author’s name and likeness in connection with any past, present or future promotional activity by ACC, including, but not limited to, promotions for upcoming issues or publications, circulation solicitations, advertising or other publications in connection with ACC. Also, each of the author(s) hereby grants permission to ACC to use the manuscript in editorial research related to the improvement of editorial conduct, decision making, and issues related to peer review.
Each of the author(s) hereby releases and shall indemnify and hold harmless ACC and its successors, assigns, licensees, officers, directors, employees, and their respective heirs and representatives from and against any and all liabilities, losses, damages and expenses arising out of any claims of any kind that may be asserted against any of them based in whole or in part on any breach of the author(s)’ representations or warranties herein or in the work or anything contained in the work, including but not limited to any claims for copyright infringement or violation of any rights of privacy or publicity.
